Overview
Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitisPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Boehringer IngelheimTreatments:
Indomethacin
Meloxicam
Criteria
Inclusion Criteria:- Active ankylosing spondylitis (pain rated >= 40 mm on a VAS and increased of at least
30% after nonsteroidal anti-inflammatory drugs (NSAIDs) wash-out)), without peripheral
arthritis and inflammatory bowel disease
Exclusion Criteria:
none